Leo Lens Technology (LLT) has developed a proprietary technology enabling sustained release of ocular drugs via contact lenses. The use of cutting-edge digital printing technology, with 3D printing concepts, allows the firm not only digitally to print âdrug-loaded inkâ on the surface of existing FDA-approved contact lenses, but to also modulate the drug release rate by building appropriate 3D drug reservoirs and barrier layers - effectively enabling a new application for contact lenses as drug delivery devices potentially applicable for ocular diseases like glaucoma, allergy, infection, and dry eye. With an aging population, glaucoma alone poses a serious public health challenge and is the second leading cause of irreversible blindness if left untreated. Traditionally, glaucoma is treated with topical medications, such as eye drops. However, topical treatments face problems such as low bioavailability, increased side effects, and poor patient compliance. Alternatively, invasive treatments are available, but they are cost-prohibitive and require continuous follow-up for most patients. LLT offers a solution that allows for increased patient compliance with minimal cost difference compared to existing topical treatme
